Skip to main content
. 2017 Jan 1;8(1):104–110. doi: 10.7150/jca.16856

Figure 2.

Figure 2

Diagnostic value of FR+-CTCs in patients with lung cancer. (A) FR+-CTC levels in patients with lung cancer, benign lung disease and healthy controls. (B) ROC curve for FR+-CTC in discriminating patients with lung cancer from patients with benign lung disease and healthy controls. (C) ROC curve for FR+-CTC combined with tumor marker in discriminating patients with lung cancer from patients with benign lung disease and healthy controls.